UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | May 31, 2012 |
Endocyte, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 001-35050 | 35-1969-140 |
|
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana | 47906 | |
|
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 765-463-7175 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Endocyte, Inc. (the “Company”) held its annual meeting of stockholders on May 31, 2012. Stockholders took the following actions:
| • | elected three (3) directors for three-year terms ending at the 2015 annual meeting of stockholders (Proposal 1); and |
| • | ratified the Audit Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2012 (Proposal 2). |
The vote tabulation for each proposal follows:
Proposal 1 – Election of Directors
| Broker | ||||||||||||
| Nominee | For | Withhold | Non-Votes | |||||||||
Keith E. Brauer |
20,542,873 | 172,117 | 6,937,742 | |||||||||
Ann F. Hanham, PhD. |
20,529,772 | 185,218 | 6,937,742 | |||||||||
Peter D. Meldrum |
20,331,793 | 383,197 | 6,937,742 | |||||||||
Proposal 2 – Ratification of Independent Registered Public Accounting Firm
| For | Against | Abstained | Broker Non-Votes | |||||||||||||||
27,637,328
|
15,384 | 20 | 0 | |||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Endocyte, Inc. | ||||
| June 1, 2012 | By: |
/s/ Michael A. Sherman
|
||
|
|
||||
| Name: Michael A. Sherman | ||||
| Title: Chief Financial Officer | ||||